{"id":"oral-topotecan","safety":{"commonSideEffects":[{"rate":"40-80","effect":"Neutropenia"},{"rate":"25-50","effect":"Anemia"},{"rate":"25-50","effect":"Thrombocytopenia"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"20-40","effect":"Diarrhea"},{"rate":"25-40","effect":"Fatigue"},{"rate":"15-30","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Topotecan is a camptothecin derivative that binds to and stabilizes the topoisomerase I-DNA complex, preventing DNA religation and leading to double-strand breaks during replication. This results in apoptosis of rapidly dividing cancer cells. The oral formulation provides an alternative to intravenous administration, potentially improving patient convenience and tolerability.","oneSentence":"Oral topotecan inhibits topoisomerase I, an enzyme required for DNA replication, causing DNA damage and cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:52.320Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Cervical cancer"}]},"trialDetails":[{"nctId":"NCT03289910","phase":"PHASE2","title":"Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-24","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia","enrollment":25},{"nctId":"NCT05353439","phase":"PHASE1","title":"Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-27","conditions":"Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma","enrollment":18},{"nctId":"NCT03896503","phase":"PHASE2","title":"Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-30","conditions":"Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma","enrollment":104},{"nctId":"NCT02298348","phase":"PHASE1","title":"Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2015-10-08","conditions":"Neuroblastoma","enrollment":18},{"nctId":"NCT07214779","phase":"PHASE3","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-12-09","conditions":"Ovarian Cancer","enrollment":466},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT06449209","phase":"PHASE2","title":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2024-08-05","conditions":"Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer","enrollment":110},{"nctId":"NCT05153239","phase":"PHASE3","title":"Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaMar","startDate":"2022-07-22","conditions":"Relapsed Small Cell Lung Cancer","enrollment":705},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT07371663","phase":"PHASE1, PHASE2","title":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Beijing Tide Pharmaceutical Co., Ltd","startDate":"2025-12-03","conditions":"Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer","enrollment":266},{"nctId":"NCT07365241","phase":"PHASE3","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-04-14","conditions":"Small Cell Lung Cancer","enrollment":531},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT01231906","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2010-11-24","conditions":"Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues","enrollment":642},{"nctId":"NCT06930755","phase":"PHASE1","title":"Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer","status":"RECRUITING","sponsor":"Nerviano Medical Sciences","startDate":"2026-01-31","conditions":"Ovarian Cancer","enrollment":24},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT07321912","phase":"PHASE2","title":"Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-04-01","conditions":"Osteosarcoma, Ewing Sarcoma, Ewing Sarcoma Metastatic","enrollment":406},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT05521984","phase":"PHASE1","title":"Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-04-03","conditions":"Pediatric Brain Tumor, Pediatric Solid Tumor","enrollment":20},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT01012817","phase":"PHASE1, PHASE2","title":"Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-11-03","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma","enrollment":88},{"nctId":"NCT03107988","phase":"PHASE1","title":"NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2017-09-05","conditions":"Neuroblastoma","enrollment":65},{"nctId":"NCT07141771","phase":"PHASE1, PHASE2","title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-12-31","conditions":"SCLC, Extensive Stage","enrollment":100},{"nctId":"NCT01931098","phase":"PHASE2","title":"Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-10","conditions":"Glioblastoma, Glioblastoma Multiforme, Gliosarcoma","enrollment":35},{"nctId":"NCT04106219","phase":"PHASE1","title":"A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-06-11","conditions":"Neuroblastoma","enrollment":71},{"nctId":"NCT04239092","phase":"PHASE1","title":"9-ING-41 in Pediatric Patients With Refractory Malignancies.","status":"TERMINATED","sponsor":"Actuate Therapeutics Inc.","startDate":"2020-06-05","conditions":"Refractory Cancer, Refractory Neoplasm, Cancer Pediatric","enrollment":40},{"nctId":"NCT05101551","phase":"PHASE1","title":"Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy","status":"RECRUITING","sponsor":"Norman J. Lacayo","startDate":"2023-02-23","conditions":"Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT03554473","phase":"PHASE1, PHASE2","title":"M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-11","conditions":"Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT00588991","phase":"PHASE1","title":"Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-04","conditions":"Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia","enrollment":12},{"nctId":"NCT04421547","phase":"PHASE3","title":"Efficacy of Letrozole in Recurrent Ovarian Cancer","status":"TERMINATED","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2020-06-22","conditions":"Epithelial Ovarian Cancer","enrollment":86},{"nctId":"NCT04514497","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-20","conditions":"Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Neuroendocrine Carcinoma","enrollment":28},{"nctId":"NCT02030964","phase":"PHASE1","title":"N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2014-01-16","conditions":"Neuroblastoma","enrollment":30},{"nctId":"NCT03709680","phase":"PHASE2","title":"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-05-24","conditions":"Ewing Sarcoma, Solid Tumors, Rhabdoid Tumor","enrollment":128},{"nctId":"NCT04029688","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-01-27","conditions":"Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma","enrollment":38},{"nctId":"NCT02312245","phase":"PHASE2","title":"Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2015-07-21","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":13},{"nctId":"NCT01904253","phase":"PHASE2","title":"A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2013-07","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":18},{"nctId":"NCT06548763","phase":"PHASE2","title":"Oral Topotecan With Toripalimab for Patients With Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-11-30","conditions":"Endometrial Cancer","enrollment":30},{"nctId":"NCT00881166","phase":"PHASE1","title":"Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2007-11","conditions":"Malignant Disease","enrollment":101},{"nctId":"NCT01798004","phase":"PHASE1","title":"Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-09","conditions":"Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma","enrollment":150},{"nctId":"NCT02308527","phase":"PHASE2","title":"Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Birmingham","startDate":"2013-07","conditions":"Neuroblastoma","enrollment":225},{"nctId":"NCT01606878","phase":"PHASE1","title":"Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2013-04-29","conditions":"Childhood Solid Neoplasm, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Neuroblastoma","enrollment":46},{"nctId":"NCT02649673","phase":"PHASE1","title":"LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies","status":"TERMINATED","sponsor":"SCRI Development Innovations, LLC","startDate":"2016-03-23","conditions":"Small Cell Lung Cancer, Ovarian Cancer","enrollment":34},{"nctId":"NCT03600649","phase":"PHASE1","title":"Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas","status":"UNKNOWN","sponsor":"Salarius Pharmaceuticals, LLC","startDate":"2018-06-04","conditions":"Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue","enrollment":50},{"nctId":"NCT02584478","phase":"PHASE3","title":"Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)","status":"UNKNOWN","sponsor":"Advenchen Laboratories, LLC","startDate":"2015-12","conditions":"Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma","enrollment":294},{"nctId":"NCT01849874","phase":"PHASE3","title":"A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2013-06-27","conditions":"Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer","enrollment":341},{"nctId":"NCT00856037","phase":"PHASE1","title":"Topotecan Hydrochloride and Doxorubicin Hydrochloride in Treating Relapsed or Refractory Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2009-02-02","conditions":"Recurrent Small Cell Lung Carcinoma","enrollment":22},{"nctId":"NCT05295589","phase":"PHASE2","title":"Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-30","conditions":"Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT00057837","phase":"PHASE2","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-07-14","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":140},{"nctId":"NCT03236857","phase":"PHASE1","title":"A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-11-08","conditions":"Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)","enrollment":143},{"nctId":"NCT05736952","phase":"PHASE2","title":"Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-03-01","conditions":"Platinum-resistant Ovarian Cancer","enrollment":""},{"nctId":"NCT02282020","phase":"PHASE3","title":"Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-06","conditions":"Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity","enrollment":266},{"nctId":"NCT05303727","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2022-08","conditions":"Neuroblastoma","enrollment":64},{"nctId":"NCT02357810","phase":"PHASE2","title":"Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-03-21","conditions":"Adult Liposarcoma, Metastatic Liposarcoma, Metastatic Osteosarcoma","enrollment":178},{"nctId":"NCT00567567","phase":"PHASE3","title":"Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-11-05","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":665},{"nctId":"NCT03987685","phase":"PHASE1","title":"Evaluate Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"Athenex, Inc.","startDate":"2018-07-19","conditions":"Solid Tumor","enrollment":10},{"nctId":"NCT00317772","phase":"PHASE1, PHASE2","title":"Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-09-02","conditions":"Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer","enrollment":19},{"nctId":"NCT00499616","phase":"PHASE3","title":"Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-10-08","conditions":"Neuroblastoma","enrollment":464},{"nctId":"NCT03541928","phase":"PHASE2","title":"Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-08-02","conditions":"High-risk Prostate Cancer, Prostate Cancer","enrollment":60},{"nctId":"NCT03061812","phase":"PHASE3","title":"Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-11","conditions":"Small Cell Lung Cancer","enrollment":444},{"nctId":"NCT03059667","phase":"PHASE2","title":"Immunotherapy as Second-line in Patient With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2017-03-13","conditions":"Small Cell Lung Cancer, Small Cell Lung Cancer Limited Stage, Small Cell Lung Cancer Extensive Stage","enrollment":73},{"nctId":"NCT02822157","phase":"PHASE2","title":"Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-08","conditions":"Ovarian Epithelial Cancer","enrollment":160},{"nctId":"NCT02390843","phase":"PHASE1","title":"Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-02","conditions":"Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma","enrollment":13},{"nctId":"NCT04073550","phase":"PHASE3","title":"Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2019-10-31","conditions":"Small Cell Lung Cancer","enrollment":184},{"nctId":"NCT04055038","phase":"PHASE2, PHASE3","title":"Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2019-09-01","conditions":"Ovarian Cancer, Ovarian Neoplasms, Serous Adenocarcinoma","enrollment":164},{"nctId":"NCT01266447","phase":"PHASE2","title":"Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma","enrollment":27},{"nctId":"NCT00803062","phase":"PHASE3","title":"Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-04","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":452},{"nctId":"NCT00064077","phase":"PHASE3","title":"Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2003-05","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":513},{"nctId":"NCT01654965","phase":"PHASE1","title":"Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-07-24","conditions":"Adult Solid Neoplasm","enrollment":17},{"nctId":"NCT00259935","phase":"PHASE1","title":"A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-10-04","conditions":"Lung Cancer, Small Cell","enrollment":107},{"nctId":"NCT00158886","phase":"PHASE1","title":"Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2001-11-08","conditions":"Carcinoma, Renal Cell","enrollment":26},{"nctId":"NCT00483860","phase":"PHASE1","title":"A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06-20","conditions":"Solid Tumours","enrollment":59},{"nctId":"NCT00732420","phase":"PHASE1","title":"Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-24","conditions":"Solid Tumours","enrollment":68},{"nctId":"NCT00004221","phase":"PHASE2","title":"Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer","status":"TERMINATED","sponsor":"Gynecologic Oncology Group","startDate":"1999-11","conditions":"Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma","enrollment":12},{"nctId":"NCT00117013","phase":"PHASE1","title":"A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-06-28","conditions":"Neoplasms","enrollment":16},{"nctId":"NCT01670175","phase":"PHASE1","title":"Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2012-08","conditions":"Malignant Solid Tumor, Childhood Solid Tumor","enrollment":21},{"nctId":"NCT00043862","phase":"PHASE2","title":"The Study Of An Oral Drug Called A Radiation Sensitizer In Patients With Newly Diagnosed Small Cell Lung Cancer (SCLC)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-08","conditions":"Lung Cancer, Small Cell, Small Cell Lung Cancer","enrollment":60},{"nctId":"NCT00046111","phase":"PHASE1","title":"A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-09","conditions":"Lung Cancer, Small Cell, Solid Tumor Cancer","enrollment":1},{"nctId":"NCT00800345","phase":"PHASE1","title":"Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors","status":"COMPLETED","sponsor":"Vector Oncology","startDate":"2009-04","conditions":"Gynecologic Tumors","enrollment":33},{"nctId":"NCT00028925","phase":"PHASE2","title":"Combination Chemotherapy With or Without Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-11","conditions":"Lung Cancer","enrollment":27},{"nctId":"NCT01600573","phase":"PHASE1, PHASE2","title":"Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)","status":"UNKNOWN","sponsor":"JSehouli","startDate":"2012-05","conditions":"Ovarian Cancer","enrollment":68},{"nctId":"NCT02348398","phase":"PHASE2","title":"Phase II Study of Pazopanib and Topotecan in Cervical Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-08","conditions":"Cervical Cancer","enrollment":""},{"nctId":"NCT00003675","phase":"PHASE2","title":"Topotecan in Treating Patients With Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1999-03","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":100},{"nctId":"NCT00033696","phase":"PHASE2","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-09","conditions":"Lung Cancer","enrollment":65},{"nctId":"NCT00004055","phase":"PHASE2","title":"Topotecan, Paclitaxel, and Filgrastim in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"1999-11","conditions":"Lung Cancer","enrollment":38},{"nctId":"NCT00006012","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2001-02","conditions":"Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity","enrollment":73},{"nctId":"NCT02738346","phase":"PHASE3","title":"SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013","status":"UNKNOWN","sponsor":"University Hospital, Angers","startDate":"2013-07","conditions":"Small Cell Lung Cancer","enrollment":164},{"nctId":"NCT01683149","phase":"PHASE1","title":"Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2013-01","conditions":"Solid Tumor","enrollment":13},{"nctId":"NCT00918320","phase":"PHASE2","title":"Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2009-06","conditions":"Neuroblastoma, Brain Tumors, Solid Tumors","enrollment":129},{"nctId":"NCT01533181","phase":"PHASE2","title":"Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02","conditions":"Recurrent Small Cell Lung Carcinoma","enrollment":44},{"nctId":"NCT00437073","phase":"PHASE2","title":"Brain Metastases In ErbB2-Positive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Neoplasms, Breast","enrollment":22},{"nctId":"NCT00739830","phase":"PHASE2","title":"Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Endometrial Cancer","enrollment":130},{"nctId":"NCT00682279","phase":"PHASE1","title":"A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2008-09","conditions":"Advanced Solid Tumors","enrollment":""},{"nctId":"NCT01037023","phase":"","title":"Regulatory Hycamtin(Oral) PMS","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Lung Cancer, Small Cell","enrollment":92},{"nctId":"NCT01047891","phase":"PHASE2","title":"Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"JSehouli","startDate":"2010-01","conditions":"Ovarian Cancer","enrollment":174},{"nctId":"NCT00807079","phase":"PHASE1, PHASE2","title":"Carboplatin and Topotecan in Treating Patients With Relapsed or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2008-09","conditions":"Cervical Cancer","enrollment":12},{"nctId":"NCT00003735","phase":"PHASE2","title":"Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1998-12","conditions":"Leukemia","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Hycamtin","Hycamtin Capsules","Oral Hycamtin","Hycamtin capsules"],"phase":"phase_3","status":"active","brandName":"Oral Topotecan","genericName":"Oral Topotecan","companyName":"Accelerated Community Oncology Research Network","companyId":"accelerated-community-oncology-research-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral topotecan inhibits topoisomerase I, an enzyme required for DNA replication, causing DNA damage and cancer cell death. Used for Small cell lung cancer, Ovarian cancer, Cervical cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}